A breakthrough study reveals a molecule, LK-2, that could revolutionize stroke treatment by selectively targeting harmful glutamate interactions in the brain, potentially leading to effective therapies with minimal side effects. Researchers have discovered a molecule, LK-2, that shows promise in treating stroke by blocking harmful glutamate activity without affecting essential brain functions. The discovery offers a new approach to developing stroke therapeutics that avoid the side effects associated with previous treatments.
A newly developed molecule, LK-2, could inform new therapies for stroke-related brain injury, finds scientists at The Hospital for Sick Children (SickKids). An ischemic stroke occurs when blood flow to a part of the brain is interrupted, depriving the brain cells of oxygen and nutrients. Without timely treatment, brain cells can die, resulting in permanent damage to the brain and its functions.
Stroke is one of the leading causes of death and disability worldwide, affecting millions every year. Breakthrough in Stroke Research An international study published today (July 10) in Nature co-led by Dr. Lu-Yang Wang, a Senior Scientist in the Neurosciences & Mental Health program at SickKids, and clinician scientists at the Shanghai Jiao Tong University School of Medicine, has uncovered a molecule that holds the potential to protect neurons during stroke and prevent stroke-related brain damage.
“Our findings provide an entirely new way to think about saving .
